Compare SEAT & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEAT | CYPH |
|---|---|---|
| Founded | 2001 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.0M | 73.3M |
| IPO Year | 2021 | 2019 |
| Metric | SEAT | CYPH |
|---|---|---|
| Price | $2.80 | $2.84 |
| Analyst Decision | Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $11.68 | N/A |
| AVG Volume (30 Days) | 71.4K | ★ 12.1M |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 103.87 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.82 | $408.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.74 | $0.49 |
| 52 Week High | $13.87 | $4.19 |
| Indicator | SEAT | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 25.52 | 50.09 |
| Support Level | N/A | $0.65 |
| Resistance Level | $7.68 | $3.23 |
| Average True Range (ATR) | 0.24 | 0.37 |
| MACD | 0.06 | -0.05 |
| Stochastic Oscillator | 0.00 | 43.19 |
Vivid Seats Inc is an online ticket marketplace for connecting fans to live events and artists. It is the official ticketing partner of brands in the entertainment industry, providing tickets for sports, concerts, theatres, and comedy events in the United States, Canada, and Japan. It operates in two segments: Marketplace, which generates maximum revenue, and Resale. The Marketplace segment acts as an intermediary between ticket buyers, sellers, and partners, earning revenue from processing ticket sales for live events and facilitating the booking of hotel rooms and packages on websites and mobile applications. The Resale segment acquires tickets to resell on secondary ticket marketplaces, including its own, and offers internal research and development support for Skybox.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.